Health

Add as a preferred source on Google

FDA Rejects Summit's U.S. Application for ivonescimab Lung Cancer Drug

Summit said its global study slowed cancer progression, while The Straits Times reported the FDA wanted clearer evidence on survival.

Updated 1 min read
Staff enter the FDA White Oak campus in Silver Spring, Maryland, on an overcast morning. / TokenPost.ai
Staff enter the FDA White Oak campus in Silver Spring, Maryland, on an overcast morning. / TokenPost.ai

The U.S. Food and Drug Administration (FDA) rejected Summit Therapeutics' application for ivonescimab, a lung cancer drug invented in China by Akeso Biopharma, after trial results did not establish longer survival, The Straits Times reported.

Summit disclosed the agency's decision in a Nov. 15 release, the newspaper reported. Akeso licensed the drug to Summit, a Florida-based company seeking U.S. approval, according to The Straits Times.

Summit said ivonescimab held back disease progression in a global study. The Straits Times reported that the FDA wanted clearer proof the drug extended patients' lives because the study did not show a statistically significant survival gain. EconoTimes previously covered Summit's account of the FDA's survival concerns.

The rejection has weakened expectations that ivonescimab could challenge Keytruda, the newspaper reported. It said the medicine is also being tested for colon, bladder and breast cancers.

Related articles

View all